Cargando…

First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma

Despite multimodal therapy, the prognosis of patients with metastatic Ewing sarcoma (ES) remains poor, with new treatments urgently needed. The disialoganglioside GD2, a well-established tumor-associated antigen, is expressed in 40% to 90% of ES cells, making it a suitable therapeutic target. Here w...

Descripción completa

Detalles Bibliográficos
Autores principales: Spasov, Neofit J., Dombrowski, Frank, Lode, Holger N., Spasova, Mariya, Ivanova, Liliya, Mumdjiev, Ivan, Burnusuzov, Hassan, Siebert, Nikolai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323561/
https://www.ncbi.nlm.nih.gov/pubmed/35622995
http://dx.doi.org/10.1097/MPH.0000000000002488
_version_ 1784756581203705856
author Spasov, Neofit J.
Dombrowski, Frank
Lode, Holger N.
Spasova, Mariya
Ivanova, Liliya
Mumdjiev, Ivan
Burnusuzov, Hassan
Siebert, Nikolai
author_facet Spasov, Neofit J.
Dombrowski, Frank
Lode, Holger N.
Spasova, Mariya
Ivanova, Liliya
Mumdjiev, Ivan
Burnusuzov, Hassan
Siebert, Nikolai
author_sort Spasov, Neofit J.
collection PubMed
description Despite multimodal therapy, the prognosis of patients with metastatic Ewing sarcoma (ES) remains poor, with new treatments urgently needed. The disialoganglioside GD2, a well-established tumor-associated antigen, is expressed in 40% to 90% of ES cells, making it a suitable therapeutic target. Here we report 3 cases with newly diagnosed, metastatic, GD2-positive ES or Ewing-like sarcoma treated with the anti-GD2 antibody dinutuximab beta in addition to standard chemotherapeutic regimens. Treatment was well-tolerated, and all patients achieved complete remission, without evidence of relapse. First-line anti-GD2 immunotherapy in patients with metastatic, GD2-positive ES or Ewing-like sarcoma represents a promising therapeutic option that warrants further clinical evaluation.
format Online
Article
Text
id pubmed-9323561
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-93235612022-08-03 First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma Spasov, Neofit J. Dombrowski, Frank Lode, Holger N. Spasova, Mariya Ivanova, Liliya Mumdjiev, Ivan Burnusuzov, Hassan Siebert, Nikolai J Pediatr Hematol Oncol Online Articles: Clinical and Laboratory Observations Despite multimodal therapy, the prognosis of patients with metastatic Ewing sarcoma (ES) remains poor, with new treatments urgently needed. The disialoganglioside GD2, a well-established tumor-associated antigen, is expressed in 40% to 90% of ES cells, making it a suitable therapeutic target. Here we report 3 cases with newly diagnosed, metastatic, GD2-positive ES or Ewing-like sarcoma treated with the anti-GD2 antibody dinutuximab beta in addition to standard chemotherapeutic regimens. Treatment was well-tolerated, and all patients achieved complete remission, without evidence of relapse. First-line anti-GD2 immunotherapy in patients with metastatic, GD2-positive ES or Ewing-like sarcoma represents a promising therapeutic option that warrants further clinical evaluation. Lippincott Williams & Wilkins 2022-08 2022-05-27 /pmc/articles/PMC9323561/ /pubmed/35622995 http://dx.doi.org/10.1097/MPH.0000000000002488 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Online Articles: Clinical and Laboratory Observations
Spasov, Neofit J.
Dombrowski, Frank
Lode, Holger N.
Spasova, Mariya
Ivanova, Liliya
Mumdjiev, Ivan
Burnusuzov, Hassan
Siebert, Nikolai
First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma
title First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma
title_full First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma
title_fullStr First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma
title_full_unstemmed First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma
title_short First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma
title_sort first-line anti-gd2 therapy combined with consolidation chemotherapy in 3 patients with newly diagnosed metastatic ewing sarcoma or ewing-like sarcoma
topic Online Articles: Clinical and Laboratory Observations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323561/
https://www.ncbi.nlm.nih.gov/pubmed/35622995
http://dx.doi.org/10.1097/MPH.0000000000002488
work_keys_str_mv AT spasovneofitj firstlineantigd2therapycombinedwithconsolidationchemotherapyin3patientswithnewlydiagnosedmetastaticewingsarcomaorewinglikesarcoma
AT dombrowskifrank firstlineantigd2therapycombinedwithconsolidationchemotherapyin3patientswithnewlydiagnosedmetastaticewingsarcomaorewinglikesarcoma
AT lodeholgern firstlineantigd2therapycombinedwithconsolidationchemotherapyin3patientswithnewlydiagnosedmetastaticewingsarcomaorewinglikesarcoma
AT spasovamariya firstlineantigd2therapycombinedwithconsolidationchemotherapyin3patientswithnewlydiagnosedmetastaticewingsarcomaorewinglikesarcoma
AT ivanovaliliya firstlineantigd2therapycombinedwithconsolidationchemotherapyin3patientswithnewlydiagnosedmetastaticewingsarcomaorewinglikesarcoma
AT mumdjievivan firstlineantigd2therapycombinedwithconsolidationchemotherapyin3patientswithnewlydiagnosedmetastaticewingsarcomaorewinglikesarcoma
AT burnusuzovhassan firstlineantigd2therapycombinedwithconsolidationchemotherapyin3patientswithnewlydiagnosedmetastaticewingsarcomaorewinglikesarcoma
AT siebertnikolai firstlineantigd2therapycombinedwithconsolidationchemotherapyin3patientswithnewlydiagnosedmetastaticewingsarcomaorewinglikesarcoma